Zhitong Finance APP was informed that the Heroy-B (02256) rose by more than 4%. As of press time, it rose 4.17%to HK $ 2.59,200.
On the message, and reputation, on February 23, the companys subsidiaries and Yuxi Pharmaceutical announced that its independently developed EGFR EXON20INS inhibitor ABSK112 was targeted at (NSCLC) The first clinical trial of the first patient was administered.Earlier, ABSK112 has obtained clinical research permits from the National Drug Administration (NMPA) and the US Food and Drug Administration (FDA), and conducts phase I clinical trials in China and the United States simultaneously.
This article comes from Zhitong Finance Network
